Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
February 2006
in “
Current pharmaceutical design
”
Studysummary This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discussed the development and effectiveness of 5α-reductase inhibitors, such as finasteride and dutasteride, in treating benign prostatic hyperplasia (BPH). These inhibitors work by reducing dihydrotestosterone (DHT) levels in the prostate, which decreases prostate volume and improves urinary symptoms. Alpha-1 adrenergic antagonists, like doxazocin and tamsulosin, also help by relaxing the bladder neck and prostate muscles, improving urine flow. While α1-adrenergic antagonists are effective short-term, 5α-reductase inhibitors provide long-term benefits, especially for men with larger prostates, by reducing the risk of urinary retention and the need for surgery. Combining both drug classes significantly improves outcomes compared to using either alone.
